Wyeth submits follow-up to antidepressant blockbuster
January 20, 2006Sales and Marketing
Wyeth has submitted its new antidepressant desvenlafaxine to the FDA, a drug it hopes will be a successor to its …
Next generation hypertension drug ready for 2006 filing
January 20, 2006Sales and Marketing
Next generation hypertension drug aliskiren is on track for filing in late 2006 and is showing promising results in the …
Campaign to raise awareness of pharma code of conduct
January 20, 2006Medical Communications
The UK pharmaceutical industry's newly re-drafted code of conduct is to benefit from a PR campaign to promote awareness of …
Next generation monoclonal antibodies to enter clinical trials in 2007
January 20, 2006Research and Development Ablynx, Novartis
Novartis has signed a deal with Belgium biotech Ablynx to develop the next generation of monoclonal antibodies with clinical development …
FDA looks to streamline early research
January 19, 2006Research and Development
The FDA has unveiled plans to allow more small-scale exploratory studies of drugs in humans before formal phase I studies …
Novartis to appeal Zelnorm rejection
January 18, 2006Sales and Marketing
Novartis says it will appeal against an EMEA decision not to recommend its irritable bowel syndrome drug Zelnorm. Zelnorm (tegaserod) …
Prescribers ready to defy NICE in Alzheimer’s drug row
January 18, 2006Sales and Marketing
Patient groups and manufacturers are hoping NICE will reverse its decision to deny access to Alzheimer's drugs on the NHS, …
First-in-class indication expected for Remicade
January 18, 2006Sales and Marketing
Schering-Plough expects its arthritis treatment Remicade to receive European approval to treat ulcerative colitis in early 2006.If approved Remicade (infliximab) …
StayinFront wins Roche regional contract
January 18, 2006Business Services
Roche will equip its Central and Eastern European salesforces with StayinFront customer relationship management software after expanding its current contract …
Patient-led NHS revolution to continue, says under fire Hewitt
January 18, 2006Patricia Hewitt has pledged to press ahead with the next phase of Labour's NHS reforms, despite renewed opposition from within …
Merck in race to bring first cervical cancer vaccine to market
January 18, 2006Sales and Marketing
Merck and GlaxoSmithKline are head-to-head in a race to establish a market for their rival cervical cancer vaccines, both set …
Drinking straw a novel antibiotic delivery for children
January 17, 2006Sales and Marketing
A new drinking straw that administers antibiotics to children as they drink has been launched by German pharma company Grunenthal.Clarosip …
Virgo Health wins Cymbalta account
January 17, 2006Medical Communications
Virgo Health has been appointed to promote depression brand Cymbalta to healthcare professionals in the UK following a two-way competitive …
Right time, right place, right patient
January 17, 2006Research and Development
With patient recruitment such a key cog in the overall clinical trial machine, pharma and biotech businesses are increasing their …
Pfizer to go it alone with Exubera
January 16, 2006Sales and Marketing Exubera, Pfizer, diabetes, inhaled insulin
Pfizer has paid $1.3 billion to buy out its marketing partner’s stake in new inhaled diabetes drug Exubera.The US company …
Gene discovery offers new diabetes drug target hope
January 16, 2006Research and Development
A gene thought to be present in around 20% of type II diabetes patients has been identified, opening up the …
Unfamiliar territory
January 13, 2006At this year's NHS Confederation conference in June, the most debated corridor question was whether or not there would be …
Patients unaware as flagship NHS choice scheme launched
January 12, 2006Primary Care Trusts across England have launched an unprecedented marketing campaign to promote the new NHS choice agenda to patients.From …
Packer Forbes wins Remicade and Altana accounts
January 12, 2006Medical Communications
Packer Forbes has won new accounts from Schering-Plough for the arthritis treatment Remicade and from Altana Pharma for the company's …
Bayer buys hypertension drug rights from GSK
January 12, 2006Sales and Marketing
Bayer has bought the rights to market the hypertension drug telmisartan in a number of European markets from current licence …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
